Navigation Links
Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System

D Garteiz, TexMS Analytical Services, Houston, TX

Introduction

A Varian 1200L LC/MS/MS system was used for the quantitation of the plasma levels oxybutynin obtained by topical delivery of therapeutic agents to the urinary tract using a urethra suppository mode of administration.

Background Urinary tract disease is a major health problem in the U.S. and will continue to grow with an increasingly aging population. Urinary incontinence accounts for over ten million patients suffering from urinary tract disease in the United States. Although oral delivery of drugs is an effective method of treating incontinence, many patients are unable to continue oral drug therapy because of severe side effects such as dry mouth, nausea, and tachycardia. One method of satisfying the clinical need of treating patients refractory to oral medication is through topical delivery of therapeutic agents to the urinary tract. The urethra provides an accessible and potentially effective method for achieving topical drug delivery to the urinary tract and surrounding organs and tissues.

One of the most commonly used drugs for urinary tract disease is oxybutynin chloride (Figure 1). Because of the severity of the drugs side effects, low doses are administered, leading to oxybutynin plasma levels that can range from the low pg/mL to low ng/mL. The present study investigates the feasibility of providing therapeutic agents to the urinary tract by absorption through the urethra.

Using a rabbit model, urethral suppositories, formulated with oxybutynin chloride were placed in the urethra of female rabbits. The suppositories liquefy in the urethra and transfer the oxybutynin through the urethral mucosal into the systemic circulation. Safety of urethral absorption of oxybutynin was established by comparing the plasma levels of urethral absorption of oxybutynin versus levels achieved by intravesical administration (injection in the bladder) of the drug.

Instrumentation

Varian 1200L LC/MS/MS equipped with Electrospray Ionization (ESI) source

Materials and Reagents

Oxybutynin chloride from Sigma-Aldrich, Catalog Number O2881.

Diphenhydramine hydrochloride from Sigma-Aldrich, Catalog Number D3630.

All other chemicals are reagent grade or HPLC grade.

Sample Preparation

A 0.5 mL aliquot of rabbit EDTA plasma containing oxybutynin chloride is spiked with 10 μL of diphenhydramine (0.5 ng/mL) as the internal standard (ISTD). Plasma is made basic and extracted with methyl t-butyl ether.

After separation of the phases by centrifugation, the organic layer is transferred by pouring into a conical tube and is then evaporated to dryness. The dry residue is reconstituted in 200 μL of methyl t-butyl ether and back extracted using 1% formic acid.

Results and Discussion

The ratio of the intensities of the product ions for oxybutynin to that of its internal standard [(m/z 142.3)/(m/z 167.5)] is used to calculate the oxybutynin concentration in unknown plasma samples using a calibration curve. The calibration curve is generated from the analysis of a drug free rabbit plasma matrix fortified with various amounts of oxybutynin and a fixed amount of the internal standard. The calibration curve range for the analyte is from 0.1 ng to 5.0 ng per mL of rabbit plasma

Visual examination of the calibration curve in Figure 2 shows that good linearity was obtained with the log/log curve-fitting model used. Additional sensitivity can easily be obtained by increasing the sample volume used for the assay. Figures 3 and 4 show excellent response and peak shape for both the LLOQ and ULOQ.

The pharmacokinetic plot in Figure 5 shows that oxybutynin levels are present in plasma with urethral delivery at lower doses versus intravesical delivery at higher doses. Comparing the same dose of oxybutynin for urethral and intravesical delivery methods, the urethral delivery had a lower peak level but appears to maintain a higher drug level over a greater period of time.

.

Conclusion

This study shows that the urethral delivery of oxybutynin results in a lower plasma level of drug at the same dose as intravesical delivery. The lower plasma levels resulting from urethral delivery may reduce the frequency and or severity of the undesirable side effects that have been described following intravesical administration of this drug. At the same time, the topical nature of the delivery method may improve the efficacy of the drugs pharmacological response because it is being delivered to the site of action.

Reference

1. H. Budzikiewicz and C. Djerassi, Mass Spectrometry of Organic Compounds. Holden-Day, Inc., Publishers. 1967.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantitation of Cabergoline at Extremely Low Plasma Concentrations with a Triple Quadrupole Mass Spectrometer
2. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
3. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
4. Comparison of Different Methods of mRNA Quantitation
5. Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer
6. Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer
7. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
8. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
9. Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A
10. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
11. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):